• About Us
    • About Kamari
    • The Team
    • The Board
    • Investors
    • Medical advisors
  • Science
    • TRPV3 TARGET
    • What is itch?
    • Development Pipeline
    • Our solution
  • Clinical Studies
    • Patients
    • Professionals
Kamari Pharma
  • Partnership
  • News
  • Contact
Kamari Pharma > News

News

Lichen Simplex Chronicus Itch: An Update

READ MORE >

TRPV3 antagonist treatment reduces pro-inflammatory pathways in Olmsted syndrome keratinocytes

READ MORE >

Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund

READ MORE >

© 2022 KAMARI PHARMA | Privacy Policy |  [email protected] 

Code: Epicod | Design: Overall Studio